Ux023-Cl401
ClinicalTrials.gov NCT03651505
Research payments
$4,213,630
Through program year 2025, $4,213,630 in research payments was reported against Ux023-Cl401, across 1,333 payments, paid by Ultragenyx Pharmaceutical Inc..
- Paid by
- Ultragenyx Pharmaceutical Inc.
- ClinicalTrials.gov
- NCT03651505
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,205,353 | 122 |
| 2024 | Research | $1,034,471 | 1,048 |
| 2023 | Research | $973,806 | 163 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Thomas Carpenter New Haven, CT Named on 145 payments
- Jill Simmons Nashville, TN Named on 142 payments
- Erik Imel Indianapolis, IN Named on 130 payments
- Thomas Weber Durham, NC Named on 84 payments
- Kathryn Dahir Nashville, TN Named on 83 payments
- Laila Tabatabai Houston, TX Named on 63 payments
- Anna Ryabets-Lienhard Los Angeles, CA Named on 63 payments
- Steven Ing Columbus, OH Named on 52 payments
- Gary Gottesman St. Louis, MO Named on 50 payments
- Michael Levine Philadelphia, PA Named on 49 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.